Literature DB >> 8707444

The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity.

G W Sullivan1, H T Carper, G L Mandell.   

Abstract

Monocytes and macrophages produce tumor necrosis factor-alpha (TNF alpha) in response to microbial products including endotoxin. TNF alpha is a potent primer of neutrophil (PMN) oxidative activity. Certain xanthine phosphodiesterase (PDE) inhibitors such as pentoxifylline have been shown to inhibit stimulated oxidative activity in PMN. In the present study, the non-xanthine PDE type IV inhibitor rolipram (4-[3'-cyclopentyloxy-4'-methoxyphenyl]-2-pyrrolidone) alone and in combination with adenosine is examined as a potential modulator of TNF alpha-primed PMN oxidative activity. Attainable in vivo concentrations of rolipram and physiological concentrations of adenosine alone and together synergistically decreased rhTNF alpha-primed suspended PMN oxidative activity stimulated by the chemoattractant f-met-leu-phe. The rolipram effect was reversible by washing, and rolipram had a comparable effect if added before or after priming, indicating that its effect was on the primed response rather than on priming per se. In addition, rolipram especially when combined with adenosine, decreased rhTNF alpha-stimulated PMN adherence to a fibrinogen-coated surface, and the oxidative burst of rhTNF alpha-stimulated adherent PMN. The specific adenosine A2a receptor agonists CGS 21680 and WRC-0474 had comparable activity to adenosine in these experiments. Adenosine (or CGS 21680) combined with rolipram synergistically increased f-met-leu-phe-stimulated PMN cAMP content. The effects of both adenosine and rolipram with adenosine could be only partly counteracted by treatment of the PMN with the protein kinase A inhibitor KT 5720, indicating that protein phosphorylation is only partially involved. Rolipram activity was about 1000 x (by molar concentration) greater than pentoxifylline in comparable assays. Thus, rolipram, especially when combined with adenosine, has potent modulating effects on PMN activation and may be useful in decreasing inflammatory tissue damage in patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8707444     DOI: 10.1016/0192-0561(95)00073-b

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  7 in total

Review 1.  A(2A) adenosine receptors in human peripheral blood cells.

Authors:  S Gessi; K Varani; S Merighi; E Ongini; P A Borea
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

Authors:  G W Sullivan; J M Rieger; W M Scheld; T L Macdonald; J Linden
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

3.  Blocking p21-activated kinase reduces lipopolysaccharide-induced acute lung injury by preventing polymorphonuclear leukocyte infiltration.

Authors:  Jörg Reutershan; Rebecca Stockton; Alexander Zarbock; Gail W Sullivan; Daniel Chang; David Scott; Martin A Schwartz; Klaus Ley
Journal:  Am J Respir Crit Care Med       Date:  2007-02-22       Impact factor: 21.405

Review 4.  Regulation of neutrophil function by adenosine.

Authors:  Kathryn E Barletta; Klaus Ley; Borna Mehrad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

Review 5.  Purinergic regulation of the immune system.

Authors:  Caglar Cekic; Joel Linden
Journal:  Nat Rev Immunol       Date:  2016-03       Impact factor: 53.106

6.  Mitigation of stress-induced gastric mucosal lesions by a specific type IV phosphodiesterase inhibitor.

Authors:  Sayuri Kato; Michiro Otaka; Masaru Odashima; Toshihiro Sato; Mario Jin; Tamotsu Matsuhashi; Noriaki Konishi; Sumio Watanabe
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.487

7.  Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells.

Authors:  N Germain; M Corbel; C Belleguic; E Boichot; V Lagente
Journal:  Mediators Inflamm       Date:  2001-06       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.